Upgrade your membership to see all of the expert analysis we have published on HSKA now!
Rally Above 50-Day Moving Average Line Improved Technical Stance - Wednesday, August 30, 2017
Heska (HSKA +$2.68 or +2.70% to $101.89) rose above its 50-day moving average (DMA) line ($100.56) with today's gain on higher volume, helping its outlook improve. That short-term average recently acted as resistance when rebounding. Its quarterly and annual earnings (C and A criteria) history has been strong. The small supply of only 6.1 million shares in the public float (S criteria) can contribute to greater price volatility in the event of institutional buying or selling.HSKA was highlighted in yellow with pivot point cited based on its high hit on 5/01/17 plus 10 cents in the 7/31/17 mid-day report (read here) and then summarized that evening under the headline, "Small Supply of Shares and Closed In Lower Half of Intra-day Range". It encountered distributional pressure and failed to produce confirming gains since repeatedly noted - "Subsequent gains and a strong finish above its pivot point may clinch a convincing technical buy signal. Small supply of only 6 million shares in the public float (S criteria) can contribute to greater price volatility in the event of institutional buying or selling."
Quarterly earnings increases through the Jun '17 quarter were above the +25% minimum earnings (C criteria) guideline. Since a downturn and loss in FY '13 the company's annual earnings (A criteria) increases have been strong. The company hails from the Medical - Products industry group which has a strong 96 Group Relative Strength Rating, a reassuring sign concerning the L criteria. The number of top-rated funds owning an interest rose from 184 in Sep '16 to 273 in Jun '17, a reassuring sign concerning the I criteria.
Charts used courtesy of www.stockcharts.com
Small Supply of Shares and Closed In Lower Half of Intra-day Range - Monday, July 31, 2017
Heska (HSKA +$2.74 or +2.57% to $109.54) was highlighted in yellow with pivot point cited based on its high hit on 5/01/17 plus 10 cents in the earlier mid-day report (read here). It posted a 6th consecutive gain, hitting new multi-year highs, but encountered distributional pressure and closed in the lower half of its intra-day range. Subsequent confirming gains and a strong finish above its pivot point may help to clinch a convincing technical buy signal.Quarterly and annual earnings (C and A criteria) history has been strong. Small supply of only 6 million shares in the public float (S criteria) can contribute to greater price volatility in the event of institutional buying or selling.
Quarterly earnings increases through the Jun '17 quarter were above the +25% minimum earnings (C criteria) guideline. Since a downturn and loss in FY '13 the company's annual earnings (A criteria) increases have been strong. The company hails from the Medical - Products industry group which has a strong 94 Group Relative Strength Rating, a reassuring sign concerning the L criteria. The number of top-rated funds owning an interest rose from 184 in Sep '16 to 263 in Jun '17, a reassuring sign concerning the I criteria.
Quarterly earnings increases through the Jun '17 quarter were above the +25% minimum earnings (C criteria) guideline. Since a downturn and loss in FY '13 the company's annual earnings (A criteria) increases have been strong. The company hails from the Medical - Products industry group which has a strong 94 Group Relative Strength Rating, a reassuring sign concerning the L criteria. The number of top-rated funds owning an interest rose from 184 in Sep '16 to 263 in Jun '17, a reassuring sign concerning the I criteria.
Charts used courtesy of www.stockcharts.com
